ReviewF1000Research2018
Recent advancements in the management of retinoblastoma and uveal melanoma.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 30 citations in OpenAlex.
- Causality-Guided Machine Learning for Retinoblastoma Survival Prediction: Development and Comparative Evaluation Using SEER.Medical sciences (Basel, Switzerland) · 2026Article
- Co-occurrence ofAmerican journal of ophthalmology case reports · 2025Article
- Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.Molecules (Basel, Switzerland) · 2024Review
- Advances in the treatment of intraocular malignancies: A literature review.Frontiers in medicine · 2022Review
- Peripapillary Neuroendocrine Carcinoma Metastasis: A Novel Approach to Treatment.Ocular oncology and pathology · 2021Article
- Piperlongumine promotes death of retinoblastoma cancer cells.Oncotarget · 2021Article
- Recent advancements in the management of retinoblastoma and uveal melanoma.Faculty reviews · 2021Review
- Intra-Arterial Chemotherapy for Retinoblastoma in Infants ≤10 kg: 74 Treated Eyes with 222 IAC Sessions.AJNR. American journal of neuroradiology · 2020Article
- Paediatric proton therapy.The British journal of radiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.